These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25908995)

  • 21. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study.
    Lombardi F; Belmonti S; Fabbiani M; Morandi M; Rossetti B; Tordini G; Cauda R; De Luca A; Di Giambenedetto S; Montagnani F
    PLoS One; 2016; 11(6):e0156523. PubMed ID: 27258647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 23-valent pneumococcal polysaccharide vaccine elicits hierarchical antibody and cellular responses in healthy and tuberculosis-cured elderly, and HIV-1-infected subjects.
    Huang H; Qian X; Pan R; Shen L; Liang S; Wang F; Zhang P; Shen H; Chen ZW
    Clin Immunol; 2018 Aug; 193():1-9. PubMed ID: 29753126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infants.
    Knuf M; Pankow-Culot H; Grunert D; Rapp M; Panzer F; Köllges R; Fanic A; Habib A; Borys D; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2012 Jan; 31(1):e31-6. PubMed ID: 21909049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.
    Sigurdardottir ST; Center KJ; Davidsdottir K; Arason VA; Hjalmarsson B; Elisdottir R; Ingolfsdottir G; Northington R; Scott DA; Jonsdottir I
    Vaccine; 2014 Jan; 32(3):417-24. PubMed ID: 24300594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children.
    Obaro SK; Huo Z; Banya WA; Henderson DC; Monteil MA; Leach A; Greenwood BM
    Pediatr Infect Dis J; 1997 Dec; 16(12):1135-40. PubMed ID: 9427458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.
    Miernyk KM; Butler JC; Bulkow LR; Singleton RJ; Hennessy TW; Dentinger CM; Peters HV; Knutsen B; Hickel J; Parkinson AJ
    Clin Infect Dis; 2009 Jul; 49(2):241-8. PubMed ID: 19522655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
    Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy.
    Tangsinmankong N; Kamchaisatian W; Day NK; Sleasman JW; Emmanuel PJ
    Ann Allergy Asthma Immunol; 2004 May; 92(5):558-64. PubMed ID: 15191025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults.
    Rossheim AE; Young AM; Siik J; Cunningham TD; Troy SB
    Hum Vaccin Immunother; 2016 Aug; 12(8):2117-2123. PubMed ID: 27172241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alterations in serotype-specific B cell responses to the 13-valent pneumococcal conjugate vaccine in aging HIV-infected adults.
    Ohtola JA; Khaskhely NM; Saul-Mcbeth JL; Iyer AS; Leggat DJ; Khuder SA; Westerink MAJ
    Vaccine; 2016 Jan; 34(4):451-457. PubMed ID: 26707220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Humoral immune responses to Streptococcus pneumoniae in the setting of HIV-1 infection.
    Zhang L; Li Z; Wan Z; Kilby A; Kilby JM; Jiang W
    Vaccine; 2015 Aug; 33(36):4430-6. PubMed ID: 26141012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
    López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
    J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 23-Valent Pneumococcal Polysaccharide Vaccine Uptake in the United States Air Force HIV Program.
    Ocampo TF; Le T; Matthews PE; Okulicz JF
    J Int Assoc Provid AIDS Care; 2016 Jul; 15(4):286-90. PubMed ID: 27215560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional immune responses to twelve serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults.
    Ahn JG; Kim HW; Choi HJ; Lee JH; Kim KH
    Vaccine; 2015 Sep; 33(38):4770-5. PubMed ID: 26277073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
    De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
    Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease - one year follow up.
    Kantsø B; Halkjær SI; Østergaard Thomsen O; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
    Infect Dis (Lond); 2019 Sep; 51(9):651-658. PubMed ID: 31290715
    [No Abstract]   [Full Text] [Related]  

  • 39. Immune response to pneumococcal conjugate vaccination in asplenic individuals.
    Stanford E; Print F; Falconer M; Lamden K; Ghebrehewet S; Phin N; Baxter D; Helbert M; McCann R; Andrews N; Balmer P; Borrow R; Kaczmarski E
    Hum Vaccin; 2009 Feb; 5(2):85-91. PubMed ID: 18758242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults.
    Feikin DR; Elie CM; Goetz MB; Lennox JL; Carlone GM; Romero-Steiner S; Holder PF; O'Brien WA; Whitney CG; Butler JC; Breiman RF
    Vaccine; 2001 Nov; 20(3-4):545-53. PubMed ID: 11672921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.